Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model

Sci Rep. 2021 Mar 18;11(1):6281. doi: 10.1038/s41598-021-85740-2.

Abstract

Pathological changes after third-generation drug-eluting stent implantation remain unclear. We compared the tissue responses of coronary arteries after the implantation of third-generation abluminal biodegradable-polymer everolimus-eluting stent (3rd EES) and second-generation durable-polymer EES (2nd EES) using autopsy specimens and an atherosclerotic porcine model. We compared the histology of stented coronary arteries obtained by autopsy performed 1-10 months after 3rd EES (n (number of cases) = 4, stent-implanted period of 3-7 months) and 2nd EES (n (number of cases) = 9, stent-implanted period of 1-10 months) implantations. The ratio of covered stent struts was higher with 3rd EESs than with 2nd EESs (3rd; 0.824 ± 0.032 vs. 2nd; 0.736 ± 0.022, p = 0.035). Low-density lipoprotein receptor knockout minipigs were stented with 3rd or 2nd EES in the coronary arteries and the stented regions were investigated. The fibrin deposition around the 2nd EES was more prominent. Additionally, higher density of smooth muscle cells was confirmed after the 3rd EES implantation. Pathological examination after the 3rd EES demonstrated a combination of less fibrin deposition and more rapid acquisition of well-developed neointima as compared to the 2nd EES at autopsy and the atherosclerotic porcine model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants / adverse effects
  • Aged
  • Aged, 80 and over
  • Animals
  • Animals, Genetically Modified
  • Autopsy
  • Coronary Artery Disease / surgery*
  • Coronary Vessels / pathology
  • Coronary Vessels / surgery
  • Disease Models, Animal*
  • Drug-Eluting Stents / adverse effects*
  • Drug-Eluting Stents / classification*
  • Everolimus / administration & dosage*
  • Female
  • Fibrin / metabolism
  • Gene Knockout Techniques
  • Humans
  • Male
  • Middle Aged
  • Neointima / etiology*
  • Neointima / metabolism
  • Percutaneous Coronary Intervention / adverse effects*
  • Plaque, Atherosclerotic / surgery
  • Prosthesis Design
  • Receptors, LDL / genetics
  • Swine / surgery*
  • Swine, Miniature / surgery*
  • Treatment Outcome

Substances

  • Receptors, LDL
  • Fibrin
  • Everolimus